<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="mena-mig01/PMC4639492/results/search/country/results.xml">
  <result pre="Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in" exact="Burkina Faso" post="TallHaoua1YaroSeydou2KpodaHervé B. N.2OuangraouaSoumeya2TrotterCaroline L.3Njanpop LafourcadeBerthe-Marie1FindlowHelen4BaiXilian4MartinCatherine1NwakammaIkenna5OuedraogoJean Bosco6GessnerBradford D.1BorrowRay4MuellerJudith E.57[1], Agence"/>
  <result pre="Institut PasteurParisFrance Presented in part: Meningitis Research Foundation Conference, London," exact="United Kingdom," post="5–6 November 2013. Poster E19. Correspondence: Judith Mueller, MD,"/>
  <result pre="and Biostatistics, Avenue du Professeur-Léon-Bernard, CS 74312, 35043 Rennes cedex," exact="France" post="(judith.mueller@ehesp.fr). ppub: 2015-11-11epub: 2015-11-11pmc-release: 2015-11-1161Suppl 5The Meningitis Vaccine Project:"/>
  <result pre="A meningococcal (MenA) conjugate vaccine, PsA-TT (MenAfriVac), was introduced in" exact="Burkina Faso" post="via mass campaigns between September and December 2010, targeting"/>
  <result pre="Conclusions. This study shows high seroprevalence against group A meningococci in" exact="Burkina Faso" post="following MenAfriVac introduction. Follow-up surveys will provide evidence on"/>
  <result pre="Vaccine Project and subsequently introduced in this region starting in" exact="Burkina Faso" post="during 2010. Vaccine was administered during mass campaigns targeting"/>
  <result pre="to evaluate anti-MenA antibody persistence after PsA-TT mass campaigns in" exact="Burkina Faso," post="by conducting 3 seroprevalence surveys in the general population"/>
  <result pre="previously have collected data on population-level anti-meningococcal immunity in Bobo-Dioulasso," exact="Burkina Faso," post="during 2008 [3], which will serve for baseline comparisons."/>
  <result pre="was approved by the National Ethics and Research Committee of" exact="Burkina Faso," post="and the Ethics Committee of Centre Muraz, Bobo-Dioulasso, Burkina"/>
  <result pre="Burkina Faso, and the Ethics Committee of Centre Muraz, Bobo-Dioulasso," exact="Burkina Faso." post="Participants or their legal guardian (if aged &amp;lt;18 years)"/>
  <result pre="serological analyses were performed at the Vaccine Evaluation Unit, Manchester," exact="United Kingdom." post="We defined malnutrition as weight for length or height"/>
  <result pre="455 (95%) had resided in Bobo-Dioulasso and 472 (98%) in" exact="Burkina Faso" post="during 2010. Two persons aged 4 and 17 years"/>
  <result pre="persons aged 4 and 17 years reported intermittent residency outside" exact="Burkina Faso" post="and no PsA-TT vaccination. Of PsA-TT eligible participants, 415"/>
  <result pre="(16%). None of the 7 persons indicating 2010 residence outside" exact="Burkina Faso" post="reported vaccination. PsA-TT vaccination was reported or confirmed by"/>
  <result pre="vaccination coverage with meningococcal group A conjugate vaccine in Bobo-Dioulasso," exact="Burkina Faso," post="2011. Estimates are given for all study participants, and"/>
  <result pre="aged 23 months to 29 years, by age group, Bobo-Dioulasso," exact="Burkina Faso," post="2011. Included are all 481 study participants who were"/>
  <result pre="Table 1. Immune Status in the General Population of Bobo-Dioulasso," exact="Burkina Faso," post="2011, by Age Group Parameter 2011 2008 All Participants"/>
  <result pre="Versus a Certainly Unvaccinated Population of the Same Age, Bobo-Dioulasso," exact="Burkina Faso," post="2008 and 2011 Age Group 2011 (PsA-TT, MenAfriVac Confirmed"/>
  <result pre="in the African meningitis belt. In an urban population of" exact="Burkina Faso," post="we found high SBAref GMTs of almost 2000, with"/>
  <result pre="example, a recent study of PsA-TT trial data in The" exact="Gambia" post="evaluated the impact of preexisting antibody on immune responses"/>
  <result pre="been underestimated in our study. In a neighboring region in" exact="Burkina Faso," post="a survey showed PsA-TT coverage ranging from 71% (overall,"/>
  <result pre="in Bobo-Dioulasso (Weekly reports 2011–2015 by the Ministry of Health," exact="Burkina Faso" post="[&quot;Situation épidémiologique hebdomadaire,&quot; Service de surveillance épidémiologique, Direction de"/>
  <result pre="MenA. The latter is suggested by large carriage studies in" exact="Burkina Faso" post="and Chad showing reduced MenA carriage following vaccine introduction"/>
  <result pre="is suggested by large carriage studies in Burkina Faso and" exact="Chad" post="showing reduced MenA carriage following vaccine introduction [2, 14]."/>
  <result pre="this question. Data on another MenA conjugate vaccine trialed in" exact="Denmark" post="suggest that group-specific SBA titers in young adults decrease"/>
  <result pre="continues over the longer term. Phase 2 immunogenicity trials in" exact="Mali" post="and The Gambia [1] will also conduct follow-up of"/>
  <result pre="longer term. Phase 2 immunogenicity trials in Mali and The" exact="Gambia" post="[1] will also conduct follow-up of children up to"/>
  <result pre="trials. In conclusion, this study shows high anti-meningococcal seroprevalence in" exact="Burkina Faso" post="following PsA-TT introduction. Upcoming surveys will measure the persistence"/>
  <result pre="meningitis due to group A Neisseria meningitidis by age in" exact="Burkina Faso" post="2008. PLoS One2013; 8:e55486.23457471 4MaslankaSE, GheeslingLL, LiButtiDEet al.Standardization and"/>
 </snippets>
</snippetsTree>
